Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
复制标题
肝细胞癌患者免疫检查点抑制剂治疗反应的预测性生物标志物。
DOI：
10.3390/ijms24087640
复制
发表时间：
2023-04-21
影响因子：
5.6
通讯作者：
Yang, Ju Dong
中科院分区：
文献类型：
--
作者：
Ji, Jun Ho;Ha, Sang Yun;Lee, Danbi;Sankar, Kamya;Koltsova, Ekaterina K.;Abou-Alfa, Ghassan K.;Yang, Ju Dong
肝细胞癌（HCC）是实体癌中死亡率最高的肿瘤之一。晚期诊断和缺乏有效的治疗方法是导致肝癌预后不良的原因。基于免疫检查点抑制剂（ICI）的免疫疗法已经成为癌症治疗的新里程碑。免疫疗法在包括HCC在内的一系列癌症类型中产生了显着的治疗反应。基于ICI单独治疗（程序性细胞死亡（PD）-1/程序性死亡配体1（PD-L）1抗体）的疗效，研究者开发了ICI联合治疗，包括ICI + ICI、ICI +酪氨酸激酶抑制剂（TKI）和ICI +局部治疗或新型免疫治疗。虽然这些方案已经证明了增加新药物的治疗效果，但迫切需要开发生物标志物来预测接受ICI的患者的毒性和治疗反应。在各种预测性生物标志物中，肿瘤细胞中的PD-L1表达在早期研究中受到最多关注。然而，PD-L1单独表达作为HCC的预测生物标志物的效用有限。因此，随后的研究已经评估了肿瘤突变负荷（TMB）、基因特征和多重免疫组织化学（IHC）作为预测性生物标志物的效用。在这篇综述中，我们的目的是讨论肝癌免疫治疗的现状，预测生物标志物研究的结果，以及未来的发展方向。
Hepatocellular carcinoma (HCC) has one of the highest mortality rates among solid cancers. Late diagnosis and a lack of efficacious treatment options contribute to the dismal prognosis of HCC. Immune checkpoint inhibitor (ICI)-based immunotherapy has presented a new milestone in the treatment of cancer. Immunotherapy has yielded remarkable treatment responses in a range of cancer types including HCC. Based on the therapeutic effect of ICI alone (programmed cell death (PD)-1/programmed death-ligand1 (PD-L)1 antibody), investigators have developed combined ICI therapies including ICI + ICI, ICI + tyrosine kinase inhibitor (TKI), and ICI + locoregional treatment or novel immunotherapy. Although these regimens have demonstrated increasing treatment efficacy with the addition of novel drugs, the development of biomarkers to predict toxicity and treatment response in patients receiving ICI is in urgent need. PD-L1 expression in tumor cells received the most attention in early studies among various predictive biomarkers. However, PD-L1 expression alone has limited utility as a predictive biomarker in HCC. Accordingly, subsequent studies have evaluated the utility of tumor mutational burden (TMB), gene signatures, and multiplex immunohistochemistry (IHC) as predictive biomarkers. In this review, we aim to discuss the current state of immunotherapy for HCC, the results of the predictive biomarker studies, and future direction.
登录
查看更多内容
分析肝细胞癌的基因组和转录组鉴定了转化生长因子-β途径中的突变和基因表达变化。
影响因子：
29.4
作者：
Chen J;Zaidi S;Rao S;Chen JS;Phan L;Farci P;Su X;Shetty K;White J;Zamboni F;Wu X;Rashid A;Pattabiraman N;Mazumder R;Horvath A;Wu RC;Li S;Xiao C;Deng CX;Wheeler DA;Mishra B;Akbani R;Mishra L
通讯作者：
Mishra L
影响因子：
64.5
作者：
Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu;Cancer Genome Atlas Research Network
通讯作者：
Cancer Genome Atlas Research Network
影响因子：
4.6
作者：
Bonneville R;Krook MA;Kautto EA;Miya J;Wing MR;Chen HZ;Reeser JW;Yu L;Roychowdhury S
通讯作者：
Roychowdhury S
影响因子：
13.5
作者：
Calderaro, Julien;Rousseau, Benoit;Pawlotsky, Jean-Michel
通讯作者：
Pawlotsky, Jean-Michel
AFP 通过抑制 HuR 介导的 Fas/FADD 凋亡途径促进 HCC 进展
影响因子：
9
作者：
Chen T;Dai X;Dai J;Ding C;Zhang Z;Lin Z;Hu J;Lu M;Wang Z;Qi Y;Zhang L;Pan R;Zhao Z;Lu L;Liao W;Lu X
通讯作者：
Lu X